So why didn't they publish the data pertaining to the trial? As far as I'm concerned clinical significance is just as important as statistical significance with this and the only data made available was to do with regaining smell function.
Hopefully we'll see it in the quarterly
Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-44
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.20M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $29.02K | 281.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 291994 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 72976 | 4 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 10.5¢ | 10.0¢ | 374668 | ||
| Last updated 15.00pm 06/06/2024 ? | |||||
| SPL (ASX) Chart |